FDA Approved: VITRAKVI — Supplemental Application (Loxo Oncology, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for VITRAKVI (larotrectinib) by Loxo Oncology, Inc., resulting in an updated label and/or expanded indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ntrk Gene Fusion Solid Tumors

Drugs mentioned

• Vitrakvi (larotrectinib)

Snippet

SUPPL AP for VITRAKVI (LAROTRECTINIB)